- Home
- GWH vs CASI Comparison
GWH vs CASI Comparison
Compare GWH & CASI Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- GWH
- CASI
- Stock Information
- Founded
- GWH 2011
- CASI 1991
- Country
- GWH United States
- CASI China
- Employees
- GWH N/A
- CASI N/A
- Industry
- GWH Industrial Machinery/Components
- CASI Biotechnology: Pharmaceutical Preparations
- Sector
- GWH Miscellaneous
- CASI Health Care
- Exchange
- GWH Nasdaq
- CASI Nasdaq
- Market Cap
- GWH 25.3M
- CASI 20.5M
- IPO Year
- GWH N/A
- CASI 1996
- Fundamental
- Price
- GWH $1.90
- CASI $1.36
- Analyst Decision
- GWH Hold
- CASI Strong Buy
- Analyst Count
- GWH 5
- CASI 1
- Target Price
- GWH $2.10
- CASI $4.00
- AVG Volume (30 Days)
- GWH 526.6K
- CASI 78.5K
- Earning Date
- GWH 08-13-2025
- CASI 08-15-2025
- Dividend Yield
- GWH N/A
- CASI N/A
- EPS Growth
- GWH N/A
- CASI N/A
- EPS
- GWH N/A
- CASI N/A
- Revenue
- GWH $4,155,999.00
- CASI $31,368,000.00
- Revenue This Year
- GWH $124.62
- CASI N/A
- Revenue Next Year
- GWH $245.00
- CASI N/A
- P/E Ratio
- GWH N/A
- CASI N/A
- Revenue Growth
- GWH N/A
- CASI 8.39
- 52 Week Low
- GWH $0.76
- CASI $1.09
- 52 Week High
- GWH $11.58
- CASI $7.67
- Technical
- Relative Strength Index (RSI)
- GWH 53.73
- CASI 47.65
- Support Level
- GWH $1.76
- CASI $1.21
- Resistance Level
- GWH $2.04
- CASI $1.77
- Average True Range (ATR)
- GWH 0.27
- CASI 0.12
- MACD
- GWH 0.01
- CASI 0.03
- Stochastic Oscillator
- GWH 42.78
- CASI 33.04
About GWH ESS Tech Inc.
ESS Tech Inc is a long-duration energy storage company specializing in iron flow battery technology. The company design and produce long-duration batteries predominantly using earth-abundant materials.
About CASI CASI Pharmaceuticals Inc.
CASI Pharmaceuticals Inc is a biopharmaceutical company that focuses on commercializing therapeutics and pharmaceutical products. The products include injections for patients who are suffering from leukemias and lymphomas. The EVOMELA injection is used as a conditioning treatment before autologous stem cell transplant for patients with multiple myeloma. The company products include CID-103, CNCT19, EVOMELA, MARQIBO, ZEVALIN, ENMD-2076 and others. The majority of the revenue is generated from the product sales of EVOMELA.